Literature DB >> 31315706

Screening tools to exclude active pulmonary TB in high TB burden countries: systematic review and meta-analysis.

Y Assefa1, S Woldeyohannes1, Y A Gelaw1, Y Hamada2, H Getahun2.   

Abstract

<sec> <title>OBJECTIVE</title> To examine the use of symptoms, chest X-ray (CXR) abnormalities, and combinations of symptoms and CXR in excluding active pulmonary tuberculosis (TB) before treating for latent tuberculous infection (LTBI) in high TB burden countries. </sec> <sec> <title>METHODS</title> We updated a systematic review and meta-analysis of studies on the sensitivities, specificities, predictive values, diagnostic odds ratios and areas under the curve for index tests. The analysis was conducted using the hierarchical summary receiver operating characteristic method in R software. </sec> <sec> <title>RESULTS</title> We included 24 publications in the systematic review and meta-analysis. 'Any CXR abnormality' had the highest sensitivity (94.1%, 95%CI 85.8-97.7) among all index tests. 'CXR abnormality suggestive of TB' had a higher specificity (92.2%, 95%CI 89.7-94.1) than 'any CXR abnormality' (86.8%, 95%CI 79.7-91.7). The sensitivity for 'any TB symptom' was 73.0% (95%CI 64.1-80.4), while 'prolonged cough' of ≥2 weeks had a specificity of 94.3% (95%CI 92.2-95.9). There was no significant difference in the sensitivity and specificity of all screening tools stratified by human immunodeficiency virus (HIV) settings, with the exception of 'CXR abnormality suggestive of TB', which had a significantly higher sensitivity in low than in high HIV prevalence settings (effect estimate 2.26, 95%CI 0.69-3.82; P = 0.002). </sec> <sec> <title>CONCLUSION</title> In countries with a high TB burden, the absence of any TB symptom and any CXR abnormality can be used to exclude active pulmonary TB before initiating treatment for LTBI in household contacts aged ≥5 years of patients with bacteriologically confirmed pulmonary TB. </sec>.

Entities:  

Mesh:

Year:  2019        PMID: 31315706     DOI: 10.5588/ijtld.18.0547

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

1.  "I got tested at home, the help came to me": acceptability and feasibility of home-based TB testing of household contacts using portable molecular diagnostics in South Africa.

Authors:  Andrew Medina-Marino; Lindsey de Vos; Dana Bezuidenhout; Claudia M Denkinger; Samuel G Schumacher; Sanghyuk S Shin; Wendy Stevens; Grant Theron; Martie van der Walt; Joseph Daniels
Journal:  Trop Med Int Health       Date:  2021-01-04       Impact factor: 2.622

2.  TB preventive treatment in high- and intermediate-incidence countries: research needs for scale-up.

Authors:  O Oxlade; S den Boon; D Menzies; D Falzon; M Y Lane; A Kanchar; M Zignol; A Matteelli
Journal:  Int J Tuberc Lung Dis       Date:  2021-10-01       Impact factor: 2.373

Review 3.  Symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative adults and adults with unknown HIV status.

Authors:  Anja Van't Hoog; Kerri Viney; Olivia Biermann; Bada Yang; Mariska Mg Leeflang; Miranda W Langendam
Journal:  Cochrane Database Syst Rev       Date:  2022-03-23

4.  Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR.

Authors:  Prem Perumal; Mohamed Bilal Abdullatif; Harriet N Garlant; Isobella Honeyborne; Marc Lipman; Timothy D McHugh; Jo Southern; Ronan Breen; George Santis; Kalaiarasan Ellappan; Saka Vinod Kumar; Harish Belgode; Ibrahim Abubakar; Sanjeev Sinha; Seshadri S Vasan; Noyal Joseph; Karen E Kempsell
Journal:  Front Immunol       Date:  2021-03-16       Impact factor: 7.561

5.  Health seeking behavior and associated factors among individuals with cough in Yiwu, China: a population-based study.

Authors:  Xiaoyan Sun; Shuying Luo; Lingqiao Lou; Hang Cheng; Zhen Ye; Jianwei Jia; Yina Wei; Jingbo Tao; Hanqing He
Journal:  BMC Public Health       Date:  2021-06-16       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.